News >

Expert Sheds Light on Role of Combinations, Transplant in Myeloma

Angelica Welch
Published: Friday, Oct 27, 2017

Jayesh Mehta, MD

Jayesh Mehta, MD
With a plethora of combinations available and being explored in the multiple myeloma landscape, researchers are assessing the right number of drugs to use in combination regimens.

In an interview during the meeting, Mehta shared his insight on the backbone of lenalidomide (Revlimid) and dexamethasone in combination therapies, the use of checkpoint inhibitors in multiple myeloma, and the stable role of stem cell transplantation in these patients.

OncLive: Please provide an overview of your lecture on combination therapies in multiple myeloma.

Mehta: We reviewed the role of combination therapies, and the fact that 3-drug combinations seem to be better than 2-drug combinations in relapsed myeloma. [It is unclear whether they are better] in patients who are not going to be transplanted. What is also unclear is whether 4-drug combinations are better than 3-drug combinations. Essentially, the whole point is, do we want to give multiple drugs at the same time, or give a small number of drugs first and then add in or substitute drugs later in the course of the disease? We don’t know the right answer to this. 
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How Can We Optimize Outcomes in Head and Neck Cancers with Immunotherapeutic Strategies?Oct 31, 20191.5
The Patient and Provider Connection™: Effective Communication to Optimize the Diagnosis and Management of Irritable Bowel Syndrome and Chronic Idiopathic ConstipationOct 31, 20191.0
Publication Bottom Border
Border Publication